Keywords: Ipsen, Galderma, Dysport, Distribution, YM BioSciences, Nimotuzumab, InnoKeys, CIMAB

News briefs on Ipsen/Galderma and YM BioSciences nimotuzumab assets

Article | 04 December 2012

French drugmaker Ipsen (Euronext: IPN) and Switzerland-headquartered Galderma have expanded their collaboration for the promotion and distribution of Dysport (abobotulinumtoxinA ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Galderma

YM Biosciences

Ipsen

CIMAB

InnoKeys PTE

Go to company listing

Related Drugs

nimotuzumab

Dysport

Go to drug listing